ARTICLE | Clinical News

BL-1021: Phase I started

July 18, 2011 7:00 AM UTC

BioLineRx began a double-blind, placebo-controlled, Israeli Phase I trial to evaluate single and multiple doses of 10, 20, 40 and 80 mg oral BL-1021 daily for up to 7 days in up to 56 healthy voluntee...